• Chronic Pain
  • Contact
  • Depression
  • Home
  • Privacy Policy
  • PTSD
  • Terms and Conditions
  • Video
Friday, September 22, 2023
  • Login
ketamine.news
Advertisement
  • Home
  • Depression
    ketamine news

    Bronner’s Magic Soaps Becomes The First Company to Offer Ketamine-Assisted Therapy as Part of Employees’ Health Benefits

    ketamine news

    Popular Soap Company–Dr. Bronner’s– Plans To Explore The Psychedelic Space

    ketamine news

    Psychedelic and Plant Medicine Decriminalization Efforts Spread to the Midwest.

    ketamine news

    What There is to Know About Ketamine vs. Electroconvulsive Therapy (ECT)

    ketamine news

    Dispelling the Stigmas, Ketamine, and the Future of Mental Healthcare

    ketamine news

    A First of its Kind: Wellbeing Digital Sciences Delivers its “First Ketamine Treatment Under the Inpatient KITE Program”

    ketamine news

    Aggregate Study on the Efficacy of Ketamine to Treat Depression Shows Promising Results.

    Flow Integrative - Christi Myers

    Provider Spotlight – Christi Myers, Flow Integrative

    How To Help A Depressed Person

    How To Help A Depressed Person

  • Chronic Pain
    ER Doctor Aims for Patient Centered Breakthrough: A Ketamine That Works Orally

    ER Doctor Aims for Patient Centered Breakthrough: A Ketamine That Works Orally

    Ketamine: A Paradigm Shift in Pain Management

    Ketamine: A Paradigm Shift in Pain Management

    ketamine treatment for depression

    Amidst An Opioid Crisis, Ketamine Has the Potential To Save Lives

    Ketamine for pain

    Multi-Day Low Dose Ketamine Infusion For The Treatment Of Complex Regional Pain Syndrome

    ketamine for chronic pain

    End Chronic Back Pain with Ketamine for a Fuller Life

    ketamine for pain

    What You Should Know About Rheumatoid Arthritis

    ketamine for pain

    Myofascial Pain Syndrome: Symptoms, Causes, and Treatment

    ketamine for pain

    A sweet reprieve: Ketamine helps to relive phantom limb pain

  • PTSD
    ketamine news

    Dispelling the Stigmas, Ketamine, and the Future of Mental Healthcare

    ketamine news

    A First of its Kind: Wellbeing Digital Sciences Delivers its “First Ketamine Treatment Under the Inpatient KITE Program”

    veterans day

    Veterans’ Day: What Does PTSD Look Like In Veterans?

    PTSD awareness month

    PTSD Awareness Month: What Can I Do To Help?

    Trump Orders ‘a lot’ of Ketamine for Depressed Veterans

    Will Ketamine Be A Breakthrough Drug for PTSD?

    Ketamine to treat ptsd

    PTSD Sufferers ‘Healed’ With New Ketamine Infusion Therapy?

    ketamine to treat PTSD

    VA Uses Ketamine To Treat PTSD Effectively

    ketamine to treat ptsd

    Ketamine can help treat PTSD

  • Video
  • Ketamine Directory
  • Ketamine Media
  • Contact
No Result
View All Result
  • Home
  • Depression
    ketamine news

    Bronner’s Magic Soaps Becomes The First Company to Offer Ketamine-Assisted Therapy as Part of Employees’ Health Benefits

    ketamine news

    Popular Soap Company–Dr. Bronner’s– Plans To Explore The Psychedelic Space

    ketamine news

    Psychedelic and Plant Medicine Decriminalization Efforts Spread to the Midwest.

    ketamine news

    What There is to Know About Ketamine vs. Electroconvulsive Therapy (ECT)

    ketamine news

    Dispelling the Stigmas, Ketamine, and the Future of Mental Healthcare

    ketamine news

    A First of its Kind: Wellbeing Digital Sciences Delivers its “First Ketamine Treatment Under the Inpatient KITE Program”

    ketamine news

    Aggregate Study on the Efficacy of Ketamine to Treat Depression Shows Promising Results.

    Flow Integrative - Christi Myers

    Provider Spotlight – Christi Myers, Flow Integrative

    How To Help A Depressed Person

    How To Help A Depressed Person

  • Chronic Pain
    ER Doctor Aims for Patient Centered Breakthrough: A Ketamine That Works Orally

    ER Doctor Aims for Patient Centered Breakthrough: A Ketamine That Works Orally

    Ketamine: A Paradigm Shift in Pain Management

    Ketamine: A Paradigm Shift in Pain Management

    ketamine treatment for depression

    Amidst An Opioid Crisis, Ketamine Has the Potential To Save Lives

    Ketamine for pain

    Multi-Day Low Dose Ketamine Infusion For The Treatment Of Complex Regional Pain Syndrome

    ketamine for chronic pain

    End Chronic Back Pain with Ketamine for a Fuller Life

    ketamine for pain

    What You Should Know About Rheumatoid Arthritis

    ketamine for pain

    Myofascial Pain Syndrome: Symptoms, Causes, and Treatment

    ketamine for pain

    A sweet reprieve: Ketamine helps to relive phantom limb pain

  • PTSD
    ketamine news

    Dispelling the Stigmas, Ketamine, and the Future of Mental Healthcare

    ketamine news

    A First of its Kind: Wellbeing Digital Sciences Delivers its “First Ketamine Treatment Under the Inpatient KITE Program”

    veterans day

    Veterans’ Day: What Does PTSD Look Like In Veterans?

    PTSD awareness month

    PTSD Awareness Month: What Can I Do To Help?

    Trump Orders ‘a lot’ of Ketamine for Depressed Veterans

    Will Ketamine Be A Breakthrough Drug for PTSD?

    Ketamine to treat ptsd

    PTSD Sufferers ‘Healed’ With New Ketamine Infusion Therapy?

    ketamine to treat PTSD

    VA Uses Ketamine To Treat PTSD Effectively

    ketamine to treat ptsd

    Ketamine can help treat PTSD

  • Video
  • Ketamine Directory
  • Ketamine Media
  • Contact
No Result
View All Result
ketamine.news
Home Featured

Military Invests $27M To Develop New Class Of Psychedelics-Inspired Drugs

Ketamine News by Ketamine News
June 24, 2020
in Featured, Psychedelic Medicine
0
Military Helmet

Military Helmet

3
SHARES
191
VIEWS
Share on FacebookShare on Twitter

The successful use of controlled substances such as ketamine and psilocybin mushrooms to treat mental health issues like depression and anxiety has ushered in a new era of interest in psychedelic drugs. But for researchers and clinicians eager to expand such therapies, an obvious question remains: Does treatment with psychedelics necessarily require a psychedelic experience?

An international research team hopes to answer that question by researching and developing a new class of drugs that offers the same fast-acting mental health benefits as traditional psychedelics without the disorienting, sometimes uncomfortable effects of a full-blown trip. Funded by $26.9 million from the U.S. Department of Defense’s Defense Advanced Research Projects Agency (DARPA), a new project announced this month “aims to create new medications to effectively and rapidly treat depression, anxiety, and substance abuse without major side effects,” according to a University of North Carolina (UNC) School of Medicine press release.

“Although drugs like ketamine and potentially psilocybin have rapid antidepressant actions, their hallucinogenic, addictive, and disorienting side effects make their clinical use limited,” said Brian L. Roth, a professor of pharmacology at UNC School of Medicine and the research project’s leader. “Our team has developed innovative methods and technologies to overcome these limitations with the goal of creating better medications to treat these neuropsychiatric conditions.”

Research into the possible therapeutic effects of currently illicit drugs such as ketamine, psilocybin, MDMA and others has expanded tremendously during the past decade. Nonprofit groups such as the Multidisciplinary Association for Psychedelic Studies have led the way, with university researchers and drugmakers entering the mix more recently.

In September of last year, Johns Hopkins University announced the launch of the nation’s first-ever psychedelic research center, a $17-million project to study the use of psychedelics to treat conditions such as opioid use disorder, Alzheimer’s disease, depression, anxiety and post-traumatic stress disorder (PTSD).

Government interest in psychedelic drugs has also grown. Also in September, DARPA, a federal agency that exists to support the development of emerging technologies for use by the U.S. military, announced its Focused Pharma program, meant to develop drugs “that work quickly and deliver lasting remedies for conditions such as chronic depression and post-traumatic stress.”

While that DARPA announcement didn’t mention specific substances or even use the word “psychedelics,” it referred to “certain Schedule 1 controlled drugs that engage serotonin receptors” and that have “significant side effects, including hallucination.”

The press release for the new DARPA-funded project, lead by Roth at UNC, mentions ketamine and psilocybin specifically. The team will use both biological modeling and sophisticated computational approaches in an effort to design fast-acting drugs inspired by psychedelics but free from what researchers call “disabling side effects.”

“Depression, anxiety, and substance abuse affect large segments of the population,” Roth said. “Rapidly acting drugs with antidepressant, anti-anxiety, and anti-addictive potential devoid of disabling side effects do not exist, not even as experimental compounds for use in animals. Creating such compounds would change the way we treat millions of people around the world suffering from these serious and life-threatening conditions.”

At DARPA, Dr. Tristan McClure-Begley, Focused Pharma’s program manager, said last fall that the agency’s interest in developing such drugs is due to the country’s large number of veterans with PTSD and other mental health conditions.

“It is research we need to undertake given the scale of the mental health crisis our veterans face,” he said in September, “and if it works, the payoff is a completely new, safe, and effective therapeutic option that transforms complex and previously intractable mental conditions into something more acutely treatable.”

Along with Roth at UNC Chapel Hill, the newly announced research project includes members Georgios Skiniotis and Ron Dror of Stanford University, Jian Jin of Icahn School of Medicine at Mt. Sinai, Brian Shoichet and Nevan Krogan of University of California at San Francisco and William Wetsel of Duke University.

Original article: https://www.marijuanamoment.net/military-invests-27m-to-develop-new-class-of-psychedelics-inspired-drugs/

Tags: FeaturedPsychedelic
Previous Post

Cannabis And Ketamine: Is There A Risk Of Interaction?

Next Post

People are paying $10,000 to trip on magic mushrooms at a retreat in Jamaica. But past struggles with safety and staffing show the difficulty of taking psychedelics mainstream.

Next Post
MycoMeditations is a psychedelic-retreat company in Treasure Beach, Jamaica, that facilitates 10-day trips where attendees take psychedelic, or "magic," mushrooms.

People are paying $10,000 to trip on magic mushrooms at a retreat in Jamaica. But past struggles with safety and staffing show the difficulty of taking psychedelics mainstream.

Browse by Category

  • A Day in the Life
  • Esketamine
  • Featured
  • Ketamine Dictionary
  • Ketamine for Anxiety
  • Ketamine for Depression
  • Ketamine for Pain
  • Ketamine for PTSD
  • Ketamine in The News
  • Ketamine Treatment
  • Mental Health
  • Psychedelic Medicine
  • Suicide Prevention
  • Uncategorized
ketamine news
Privacy Policy | Terms and Conditions

Categories

  • A Day in the Life
  • Esketamine
  • Featured
  • Ketamine Dictionary
  • Ketamine for Anxiety
  • Ketamine for Depression
  • Ketamine for Pain
  • Ketamine for PTSD
  • Ketamine in The News
  • Ketamine Treatment
  • Mental Health
  • Psychedelic Medicine
  • Suicide Prevention
  • Uncategorized

Recent Posts

  • Capturing the Ketamine Experience in Real Time: A First-of-its-Kind Academic Paper from Denovo Therapy
  • Connecticut Approves a Bill That Could Pave Way for the Use of Psychedelic Substances to Treat Mental Health Illnesses
  • A Group of D.C. Advocacy Groups Have Joined Hands to Push For Drug Policy Reform in the Nation’s Capital
  • ‘Magic Mushrooms’ Look Set to Follow in the Footsteps of Cannabis
  • Bronner’s Magic Soaps Becomes The First Company to Offer Ketamine-Assisted Therapy as Part of Employees’ Health Benefits
  • Chronic Pain
  • Contact
  • Depression
  • Home
  • Privacy Policy
  • PTSD
  • Terms and Conditions
  • Video

© 2023 Ketamine News

No Result
View All Result
  • Home
  • Depression
  • Chronic Pain
  • PTSD
  • Video
  • Ketamine Directory
  • Ketamine Media
  • Contact

© 2023 Ketamine News

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In